{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:27:22Z","timestamp":1785583642894,"version":"3.56.0"},"reference-count":54,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp;amp; Disease"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Most of the vaccines that are effective against SARS\u2010CoV\u20102 have used the following functional strategies: inactivated viruses, live attenuated viruses, viral vector\u2010based vaccines, subunit vaccines, recombinant proteins, and DNA\/RNA vaccines. Among the vaccines that stimulate the host's immune system with the help of DNA are: undergoing Phase 2\/3 trials including INO\u20104800 (International Vaccine Institute; Inovio Pharmaceuticals), Symvivo, Canada\u2010COVID19 (AnGes, Inc.); GX\u201019 (Genexine, Inc.). BNT162b2\u00a0and mRNA\u20101273 vaccines were made by BioNTech\/Pfizer\/Fosun Pharma group and Moderna\/NIAID group, respectively, which are considered as types of RNA vaccines. Vaccines that are based on the viral vector are AstraZeneca, Sputonium, and Johnson\u2010Jensen. Among the inactive viral vaccines, the following can be mentioned: CoronaVac (Sinovac) WIBP vaccine (Wuhan Institute of Biological Products, Sinopharm), BBIBPCorV (Beijing Institute of Biological Products, Sinopharm), BBV152\/Covaxin (Bharat Biotech, ICMR, National Institute of Virology) And among the protein\u2010based\/subunit vaccines, the following can be counted: <jats:italic>NVX\u2010CoV2373<\/jats:italic>: (Novavax); SCB\u20102019 vaccine (Clover Biopharmaceuticals AUS Pty Ltd.); <jats:italic>Covax\u201019<\/jats:italic> (GeneCure Biotechnologies; Vaxine Pty Ltd.) mRNA vaccines, viral vector vaccines, and protein subunit vaccines cannot cause disease because these vaccines stimulate the immune system to produce antibodies against virus proteins instead of the virus itself (or its antigen). MRNA vaccines increase SARS\u2010CoV\u20102 proteins and ultimately stimulate the production of T and B lymphocytes. The epidemic of HCoVs and their destructive and harmful effects on life has caused the scientific community to seek the production of an effective and efficient vaccine before its catastrophic release. We all need to know that none of us will be healed until the other is healed. The purpose of this review article is to present a selection of existing knowledge in the field of fighting and preventing the coronavirus.<\/jats:p>","DOI":"10.1002\/iid3.946","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T13:13:09Z","timestamp":1691500389000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Vaccination is the most effective and best way to avoid the disease of COVID\u201019"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6357-0911","authenticated-orcid":false,"given":"Hadi","family":"Lotfi","sequence":"first","affiliation":[{"name":"Leishmaniasis Research Center Sabzevar University of Medical Sciences Sabzevar Iran"},{"name":"Department of Medical Microbiology Sabzevar University of Medical Sciences Sabzevar Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina G.","family":"Mazar","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Science Varastegan Institute for Medical Science Mashhad Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar M. H.","family":"Ei","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Science Varastegan Institute for Medical Science Mashhad Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Fahim","sequence":"additional","affiliation":[{"name":"Mashhad University of Medical Science Mashhad Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafiseh S.","family":"Yazdi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine Sabzevar University of Medical Sciences Sabzevar Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"issue":"10","key":"e_1_2_6_2_1","first-page":"544","article-title":"Interspecies transmission and emergence of novel viruses: lessons from bats and birds","volume":"21","author":"Chan JF\u2010W","year":"2013","journal-title":"TIM"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10311-021-01187-x"},{"key":"e_1_2_6_4_1","volume-title":"Features, evaluation, and treatment of coronavirus (COVID\u201019)","author":"Cascella M","year":"2022"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2004973"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007236"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41368-020-0074-x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-020-03611-x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100426"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01648"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004895"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.043"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7003e2"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03470-x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30048-0"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2020.07.049"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6924e2"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-020-00304-9"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.00152"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6556"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2002083"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2021.07.003"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666210521164809"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2020.09.010"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2020.100295"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/odi.13916"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2639-4"},{"key":"e_1_2_6_28_1","unstructured":"Pfizer.US CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and Biontech Covid\u201019 Vaccine for Persons Ages 16 Years and Older. Pfizer; 2020."},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7004e1"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483"},{"key":"e_1_2_6_31_1","article-title":"Mutation N501Y in RBD of spike protein strengthens the interaction between COVID\u201019 and its receptor ACE2","author":"Tian F","year":"2021","journal-title":"BioRxiv"},{"key":"e_1_2_6_32_1","first-page":"620","article-title":"Neutralization of N501Y mutant SARS\u2010CoV\u20102 by BNT162b2 vaccine\u2010elicited sera","volume":"4","author":"Xie X","year":"2021","journal-title":"BioRxiv"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02183-8"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01583-4"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7020e1"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2096"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00451-5"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7038e1"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107799"},{"key":"e_1_2_6_43_1","first-page":"1101","article-title":"Comparison of two highly\u2010effective mRNA vaccines for COVID\u201019 during periods of Alpha and Delta variant prevalence","volume":"10","author":"Puranik A","year":"2021","journal-title":"MedRxiv"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114255"},{"key":"e_1_2_6_45_1","unstructured":"COVID CJ. Vaccine; Johnson & Johnson.18(1):2002083."},{"key":"e_1_2_6_46_1","volume-title":"A Randomized, Double\u2010Blind, Placebo\u2010Controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26. COV2. S for the Prevention of SARS\u2010CoV\u20102\u2010Mediated COVID\u201019 in Adults Aged 18 Years and Older","author":"Janssen Vaccines & Prevention B.V","year":"2020"},{"key":"e_1_2_6_47_1","unstructured":"LevineH.The 5 Stages of COVID\u201019 Vaccine Development: What you Need to Know about How a Clinical Trial Works. Johnson & Johnson;2020."},{"key":"e_1_2_6_48_1","unstructured":"World Health Organization.COVID\u201019 Weekly Epidemiological Update. WHO;2022."},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034201"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7009e4"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3967"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7032e4"},{"key":"e_1_2_6_53_1","unstructured":"NewsroomC.FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID\u201019 Vaccine Use Following Thorough Safety Review. Johnson & Johnson."},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004290"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2021-300266"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T11:20:05Z","timestamp":1698664805000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1002\/iid3.946"],"URL":"https:\/\/doi.org\/10.1002\/iid3.946","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"value":"2050-4527","type":"print"},{"value":"2050-4527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"2022-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e946"}}